A new generation of antiplatelet agents.


Journal Article (Review)

PURPOSE OF REVIEW: Since the development and market entry of clopidogrel, a platelet ADP blocker, physicians have had few new antiplatelet options available to them for the treatment of acute and chronic coronary disease, specifically in the setting of acute coronary syndromes, percutaneous coronary intervention, and chronic stent management. Over the years, limitations of current antiplatelet regimens have emerged, establishing a need for novel antiplatelet drugs. This article discusses potential new targets for platelet inhibition and reviews innovative antiplatelet therapies under investigation. RECENT FINDINGS: There are five main categories of antiplatelet therapies currently undergoing clinical study, consisting of the thienopyridines (P2Y12 receptor antagonists), cyclopentyltriazolopyrimidines (P2Y12 receptor antagonists), anti-von Willebrand factor aptamers, thrombin receptor (protease-activated receptor-1) antagonists, and thromboxane receptor antagonists. Early studies of these agents are discussed. SUMMARY: Each of these new antiplatelet therapies has a unique profile that is aimed at improving clinical response with hopes of incremental efficacy and decreased complications, specifically bleeding.

Full Text

Cited Authors

  • Sellers, MB; Tricoci, P; Harrington, RA

Published Date

  • July 2009

Published In

Volume / Issue

  • 24 / 4

Start / End Page

  • 307 - 312

PubMed ID

  • 19509485

Pubmed Central ID

  • 19509485

Electronic International Standard Serial Number (EISSN)

  • 1531-7080

International Standard Serial Number (ISSN)

  • 0268-4705

Digital Object Identifier (DOI)

  • 10.1097/hco.0b013e32832e2b44


  • eng